Intrinsic value of Masimo - MASI

Previous Close

$85.78

  Intrinsic Value

$41.50

stock screener

  Rating & Target

str. sell

-52%

  Value-price divergence*

-82%

Previous close

$85.78

 
Intrinsic value

$41.50

 
Up/down potential

-52%

 
Rating

str. sell

 
Value-price divergence*

-82%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MASI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 4.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  10.32
  8.80
  8.42
  8.08
  7.77
  7.49
  7.24
  7.02
  6.82
  6.64
  6.47
  6.32
  6.19
  6.07
  5.97
  5.87
  5.78
  5.70
  5.63
  5.57
  5.51
  5.46
  5.42
  5.37
  5.34
  5.30
  5.27
  5.25
  5.22
  5.20
  5.18
Revenue, $m
  695
  756
  820
  886
  955
  1,026
  1,101
  1,178
  1,258
  1,342
  1,429
  1,519
  1,613
  1,711
  1,813
  1,920
  2,031
  2,147
  2,267
  2,394
  2,526
  2,664
  2,808
  2,959
  3,117
  3,282
  3,455
  3,636
  3,826
  4,025
  4,234
Variable operating expenses, $m
 
  612
  664
  717
  773
  830
  890
  953
  1,018
  1,085
  1,155
  1,226
  1,302
  1,381
  1,464
  1,549
  1,639
  1,732
  1,830
  1,932
  2,039
  2,150
  2,266
  2,388
  2,516
  2,649
  2,789
  2,935
  3,088
  3,249
  3,417
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  274
  612
  664
  717
  773
  830
  890
  953
  1,018
  1,085
  1,155
  1,226
  1,302
  1,381
  1,464
  1,549
  1,639
  1,732
  1,830
  1,932
  2,039
  2,150
  2,266
  2,388
  2,516
  2,649
  2,789
  2,935
  3,088
  3,249
  3,417
Operating income, $m
  421
  144
  156
  169
  182
  196
  210
  225
  241
  257
  274
  293
  311
  330
  350
  370
  392
  414
  437
  462
  487
  514
  542
  571
  601
  633
  666
  701
  738
  776
  817
EBITDA, $m
  438
  162
  176
  190
  205
  220
  236
  253
  270
  288
  307
  326
  346
  367
  389
  412
  436
  461
  487
  514
  542
  572
  603
  635
  669
  704
  742
  780
  821
  864
  909
Interest expense (income), $m
  4
  0
  1
  2
  3
  4
  5
  7
  8
  9
  10
  12
  13
  15
  16
  18
  20
  22
  23
  25
  27
  30
  32
  34
  37
  39
  42
  45
  47
  51
  54
Earnings before tax, $m
  418
  144
  155
  167
  179
  192
  205
  219
  233
  248
  263
  281
  298
  315
  333
  352
  372
  392
  414
  436
  460
  484
  510
  537
  565
  594
  625
  657
  690
  726
  763
Tax expense, $m
  117
  39
  42
  45
  48
  52
  55
  59
  63
  67
  71
  76
  80
  85
  90
  95
  100
  106
  112
  118
  124
  131
  138
  145
  152
  160
  169
  177
  186
  196
  206
Net income, $m
  301
  105
  113
  122
  131
  140
  150
  160
  170
  181
  192
  205
  217
  230
  243
  257
  271
  286
  302
  319
  336
  353
  372
  392
  412
  434
  456
  479
  504
  530
  557

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  306
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  821
  560
  607
  656
  707
  760
  815
  873
  932
  994
  1,058
  1,125
  1,195
  1,268
  1,343
  1,422
  1,504
  1,590
  1,680
  1,773
  1,871
  1,973
  2,080
  2,192
  2,309
  2,431
  2,559
  2,694
  2,834
  2,982
  3,136
Adjusted assets (=assets-cash), $m
  515
  560
  607
  656
  707
  760
  815
  873
  932
  994
  1,058
  1,125
  1,195
  1,268
  1,343
  1,422
  1,504
  1,590
  1,680
  1,773
  1,871
  1,973
  2,080
  2,192
  2,309
  2,431
  2,559
  2,694
  2,834
  2,982
  3,136
Revenue / Adjusted assets
  1.350
  1.350
  1.351
  1.351
  1.351
  1.350
  1.351
  1.349
  1.350
  1.350
  1.351
  1.350
  1.350
  1.349
  1.350
  1.350
  1.350
  1.350
  1.349
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
  1.350
Average production assets, $m
  163
  178
  193
  208
  224
  241
  259
  277
  296
  315
  336
  357
  379
  402
  426
  451
  477
  504
  533
  563
  594
  626
  660
  695
  732
  771
  812
  855
  899
  946
  995
Working capital, $m
  287
  -20
  -22
  -24
  -26
  -28
  -30
  -32
  -34
  -36
  -39
  -41
  -44
  -46
  -49
  -52
  -55
  -58
  -61
  -65
  -68
  -72
  -76
  -80
  -84
  -89
  -93
  -98
  -103
  -109
  -114
Total debt, $m
  0
  23
  47
  72
  98
  124
  152
  181
  212
  243
  276
  310
  345
  382
  420
  460
  502
  545
  591
  638
  688
  739
  794
  850
  910
  972
  1,037
  1,105
  1,176
  1,251
  1,329
Total liabilities, $m
  260
  284
  308
  333
  359
  385
  413
  442
  473
  504
  537
  571
  606
  643
  681
  721
  763
  806
  852
  899
  949
  1,000
  1,055
  1,111
  1,171
  1,233
  1,298
  1,366
  1,437
  1,512
  1,590
Total equity, $m
  560
  276
  299
  324
  349
  375
  402
  430
  460
  490
  522
  555
  589
  625
  662
  701
  742
  784
  828
  874
  922
  973
  1,025
  1,081
  1,138
  1,199
  1,262
  1,328
  1,397
  1,470
  1,546
Total liabilities and equity, $m
  820
  560
  607
  657
  708
  760
  815
  872
  933
  994
  1,059
  1,126
  1,195
  1,268
  1,343
  1,422
  1,505
  1,590
  1,680
  1,773
  1,871
  1,973
  2,080
  2,192
  2,309
  2,432
  2,560
  2,694
  2,834
  2,982
  3,136
Debt-to-equity ratio
  0.000
  0.080
  0.160
  0.220
  0.280
  0.330
  0.380
  0.420
  0.460
  0.500
  0.530
  0.560
  0.590
  0.610
  0.630
  0.660
  0.680
  0.700
  0.710
  0.730
  0.750
  0.760
  0.770
  0.790
  0.800
  0.810
  0.820
  0.830
  0.840
  0.850
  0.860
Adjusted equity ratio
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493
  0.493

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  301
  105
  113
  122
  131
  140
  150
  160
  170
  181
  192
  205
  217
  230
  243
  257
  271
  286
  302
  319
  336
  353
  372
  392
  412
  434
  456
  479
  504
  530
  557
Depreciation, amort., depletion, $m
  17
  18
  20
  21
  23
  24
  26
  28
  29
  31
  33
  33
  35
  37
  39
  42
  44
  47
  49
  52
  55
  58
  61
  64
  68
  71
  75
  79
  83
  88
  92
Funds from operations, $m
  498
  123
  133
  143
  154
  164
  176
  187
  199
  212
  225
  238
  253
  267
  283
  299
  316
  333
  351
  371
  391
  411
  433
  456
  480
  505
  531
  559
  587
  617
  649
Change in working capital, $m
  81
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
Cash from operations, $m
  417
  125
  135
  145
  155
  166
  178
  189
  202
  214
  228
  241
  255
  270
  286
  302
  319
  336
  355
  374
  394
  415
  437
  460
  484
  509
  536
  563
  592
  623
  655
Maintenance CAPEX, $m
  0
  -15
  -16
  -18
  -19
  -21
  -22
  -24
  -26
  -27
  -29
  -31
  -33
  -35
  -37
  -39
  -42
  -44
  -47
  -49
  -52
  -55
  -58
  -61
  -64
  -68
  -71
  -75
  -79
  -83
  -88
New CAPEX, $m
  -24
  -15
  -15
  -16
  -16
  -17
  -17
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
Cash from investing activities, $m
  -25
  -30
  -31
  -34
  -35
  -38
  -39
  -42
  -45
  -47
  -49
  -52
  -55
  -58
  -61
  -64
  -68
  -71
  -75
  -79
  -83
  -87
  -92
  -96
  -101
  -107
  -112
  -118
  -124
  -130
  -137
Free cash flow, $m
  392
  95
  103
  111
  120
  129
  138
  147
  157
  167
  178
  188
  200
  212
  224
  237
  251
  265
  280
  295
  311
  328
  345
  364
  383
  403
  424
  446
  469
  493
  518
Issuance/(repayment) of debt, $m
  -185
  23
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  35
  37
  38
  40
  42
  44
  45
  47
  50
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
Issuance/(repurchase) of shares, $m
  -31
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -217
  23
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  35
  37
  38
  40
  42
  44
  45
  47
  50
  52
  54
  57
  59
  62
  65
  68
  71
  75
  78
Total cash flow (excl. dividends), $m
  174
  118
  127
  136
  146
  156
  166
  176
  187
  199
  211
  222
  235
  249
  263
  277
  292
  308
  325
  342
  361
  380
  399
  420
  442
  465
  489
  514
  540
  567
  596
Retained Cash Flow (-), $m
  -285
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -32
  -33
  -34
  -36
  -37
  -39
  -41
  -42
  -44
  -46
  -48
  -50
  -53
  -55
  -58
  -60
  -63
  -66
  -69
  -73
  -76
Prev. year cash balance distribution, $m
 
  306
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  402
  104
  112
  121
  129
  139
  148
  158
  168
  179
  189
  201
  213
  225
  238
  252
  266
  281
  296
  312
  329
  347
  365
  384
  404
  426
  448
  471
  495
  520
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  386
  95
  98
  99
  100
  101
  100
  99
  97
  94
  90
  86
  81
  76
  70
  64
  58
  52
  46
  40
  34
  29
  24
  20
  16
  12
  10
  7
  5
  4
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain’s electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.

FINANCIAL RATIOS  of  Masimo (MASI)

Valuation Ratios
P/E Ratio 14.3
Price to Sales 6.2
Price to Book 7.7
Price to Tangible Book
Price to Cash Flow 10.3
Price to Free Cash Flow 11
Growth Rates
Sales Growth Rate 10.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -56.4%
Cap. Spend. - 3 Yr. Gr. Rate 13%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 106
Management Effectiveness
Return On Assets 42.7%
Ret/ On Assets - 3 Yr. Avg. 23.9%
Return On Total Capital 59%
Ret/ On T. Cap. - 3 Yr. Avg. 32.3%
Return On Equity 72.1%
Return On Equity - 3 Yr. Avg. 41.3%
Asset Turnover 1
Profitability Ratios
Gross Margin 66.8%
Gross Margin - 3 Yr. Avg. 66.2%
EBITDA Margin 63.2%
EBITDA Margin - 3 Yr. Avg. 34.7%
Operating Margin 60.6%
Oper. Margin - 3 Yr. Avg. 32.4%
Pre-Tax Margin 60.1%
Pre-Tax Margin - 3 Yr. Avg. 32%
Net Profit Margin 43.3%
Net Profit Margin - 3 Yr. Avg. 23%
Effective Tax Rate 28%
Eff/ Tax Rate - 3 Yr. Avg. 28.3%
Payout Ratio 0%

MASI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MASI stock intrinsic value calculation we used $695 million for the last fiscal year's total revenue generated by Masimo. The default revenue input number comes from 2016 income statement of Masimo. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MASI stock valuation model: a) initial revenue growth rate of 8.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MASI is calculated based on our internal credit rating of Masimo, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Masimo.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MASI stock the variable cost ratio is equal to 81%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MASI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.3% for Masimo.

Corporate tax rate of 27% is the nominal tax rate for Masimo. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MASI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MASI are equal to 23.5%.

Life of production assets of 10.8 years is the average useful life of capital assets used in Masimo operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MASI is equal to -2.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $560 million for Masimo - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 50.55 million for Masimo is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Masimo at the current share price and the inputted number of shares is $4.3 billion.

RELATED COMPANIES Price Int.Val. Rating
MGCD MGC Diagnostic 7.86 2.87  str.sell
CASM CAS Medical Sy 0.960 0.03  str.sell
OMI Owens&Minor 27.60 35.08  hold
RMD ResMed 73.07 62.77  hold
BABY Natus Medical 32.50 168.19  str.buy
BDX Becton Dickins 197.69 58.16  str.sell
AHPI Allied Healthc 2.06 1.18  str.sell
OSIS OSI Systems 78.43 169.93  str.buy

COMPANY NEWS

▶ Dubai Health Authority Implements Masimo Patient SafetyNet   [Aug-14-17 12:00AM  Business Wire]
▶ Masimo beats Street 2Q forecasts   [02:15AM  Associated Press]
▶ Masimo Reports Second Quarter 2017 Financial Results   [Aug-02-17 04:05PM  Business Wire]
▶ 3 Stocks the Market Is Missing the Boat On   [Jul-14-17 06:30PM  Motley Fool]
▶ ETFs with exposure to Masimo Corp. : July 12, 2017   [Jul-12-17 02:46PM  Capital Cube]
▶ ETFs with exposure to Masimo Corp. : June 26, 2017   [Jun-26-17 04:23PM  Capital Cube]
▶ ETFs with exposure to Masimo Corp. : June 15, 2017   [Jun-15-17 02:31PM  Capital Cube]
▶ [$$] Judge Confirms Sotera Wireless Bankruptcy Plan   [May-15-17 04:04PM  The Wall Street Journal]
▶ Masimo: Cramer's Top Takeaways   [May-13-17 06:39AM  TheStreet.com]
▶ Masimo Introduces Rad-G Pulse Oximeter   [May-09-17 08:03AM  Business Wire]
▶ Indexes Trim Losses As Oil Stocks Sink; Did Tesla Flash A Sell Signal?   [May-04-17 02:49PM  Investor's Business Daily]
▶ Correction: Earns-Masimo story   [12:35PM  Associated Press]
▶ Masimo misses 1Q profit forecasts   [May-03-17 05:20PM  Associated Press]
▶ 3 Stocks to Invest in Healthcare   [Mar-26-17 02:03PM  Motley Fool]
▶ 3 Stocks to Invest in Healthcare   [02:03PM  at Motley Fool]
▶ Has Masimo Become Too Expensive to Hold?   [Mar-20-17 07:09PM  Investopedia]
▶ Has Masimo Become Too Expensive to Hold?   [07:09PM  at Investopedia]
▶ Masimo to Present at 29th Annual ROTH Conference   [Mar-06-17 09:00AM  Business Wire]
Stock chart of MASI Financial statements of MASI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.